Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14018774 | 0.84 | ALDH1A1 (0.45) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL13956708 | 0.83 | ALDH1A1 (0.44) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL15607767 | 0.82 | G6PD (0.38) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL19776259 | 0.81 | ALDH1A1 (0.50) | ALDH1A1CA2CA12CA9SMN1; SMN2 | |
| SCHEMBL11545447 | 0.80 | ALDH1A1 (0.53) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL11570200 | 0.80 | ALDH1A1 (0.47) | ALDH1A1CA2CA12CA9SMN1; SMN2 | |
| SCHEMBL15607752 | 0.79 | NPSR1 (0.41) | ALDH1A1CA1CA2SMN1; SMN2GAA | |
| SCHEMBL17222796 | 0.79 | ALDH1A1 (0.49) | ALDH1A1CA1CA2MEN1KMT2A | |
| SCHEMBL29134162 | 0.79 | ALDH1A1 (0.49) | ALDH1A1CA2SMN1; SMN2LMNAHTT | |
| SCHEMBL14132346 | 0.79 | ALDH1A1 (0.41) | ALDH1A1CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208019-A1 | CARBON FIBER BUNDLE AND METHOD FOR PRODUCING SAME | MITSUBISHI RAYON CO., LTD. (JP) | 2012-08-16 | — | — | US | disclosed |
| EP-2476799-A1 | CARBON FIBER BUNDLE AND METHOD FOR PRODUCING SAME | Mitsubishi Rayon Co., Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | GALLEY GUIDO (DE) | 2012-03-22 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| EP-1981499-A1 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007085558-A1 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| EP-0064820-A1 | Substituted imidazole and imidazoline derivatives and their preparation and use | Farmos-Yhtyma Oy (FI) | 1982-11-17 | — | — | EP | disclosed |
| US-4344958-A | BLOOD DISORDERS | THE DOW CHEMICAL COMPANY (US) | 1982-08-17 | — | — | US | disclosed |
| US-4343810-A | Method of inhibiting sickling of sickle erythrocytes using 2-((haloanilino)methyl)-2-imidazolines | THE DOW CHEMICAL COMPANY (US) | 1982-08-10 | — | — | US | disclosed |
| US-4343808-A | Method of inhibiting sickling of sickle erythrocytes | THE DOW CHEMICAL COMPANY (US) | 1982-08-10 | — | — | US | disclosed |
| US-4343809-A | ANTIANEMIA | THE DOW CHEMICAL COMPANY (US) | 1982-08-10 | — | — | US | disclosed |
| US-4136188-A | TREATMENT OF DIABETES WITH 2-SUBSTITUTED-1,3-DIAZACYCLIC COMPOUNDS | DAIICHI SEIYAKU CO., LTD. (JP) | 1979-01-23 | — | — | US | disclosed |
| US-4081544-A | ANTIDEPRESSANTS | SCHERING CORPORATION (US) | 1978-03-28 | — | — | US | disclosed |
| US-4065569-A | Use of 2-imidazolines as hypoglycemic agents | SCHERING CORPORATION (US) | 1977-12-27 | — | — | US | disclosed |
| US-3992403-A | 2-Imidazolines and their use as hypoglycemic agents | SCHERING CORPORATION (US) | 1976-11-16 | — | — | US | disclosed |
| US-3932431-A | ANTIDEPRESSANT, ANTIINFLAMMATORY | SCHERING CORPORATION (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | CRY1, PER2, GPR119 | ALDH1A1 1716/4885CA1 4534/4885CA2 2575/4885 |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | ALDH1A1 412/4885CA1 4157/4885CA2 2270/4885 |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | CRY1, PER2, GPR119 | ALDH1A1 1541/4885CA1 4500/4885CA2 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.